CannPal Granted a Permit to Possess and Supply Cannabis by NSW State Department of Health
- CannPal has been granted a permit to possess and supply tetrahydrocannabinol and cannabidiol for the purpose of scientific research by the NSW State Department of Health
- The permit allows the provision of cannabis to researchers in NSW for the purpose of CannPal’s clinical trials in Q1 CY18
- The authorisation has been issued under the provisions of the Drug Misuse and Trafficking Act 1985
- The permit will enable CannPal to seek permission from the Office of Drug Control and the Australian Pesticides and Veterinary Medicines Authority to import cannabis for its planned clinical trials
Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “the Company”) is pleased to announce it has been granted authorisation to possess and supply cannabis for scientific research by the NSW State Department of Health.
The authorisation has been issued under the provisions of the Drug Misuse and Trafficking Act 1985 and allows CannPal to apply for Australian Pesticides and Veterinary Medicines Authority (APVMA) and Office of Drug Control (ODC) permits to import cannabis for the commencement of the Company’s clinical trials planned for Q1 CY18.
CannPal has been working closely with Invetus Limited (“Invetus”), Australasia’s largest veterinary research organisation, to facilitate the importation of cannabis for scientific research in companion animals.
CannPal entered into an exclusive master research agreement with Invetus early in the year which includes a provision that allows the Company to store and research its prohibited substances at a secure purpose-built animal health research facility.
The cannabis oils being imported are for the Company’s pharmacokinetic and safety studies scheduled to take place in Q1 CY18. The University of Queensland will be providing bio-analytical services for the studies with results anticipated in Q2 CY18.
CannPal’s Founder and Managing Director Layton Mills:
Receiving the authorisation to possess and supply cannabis for research from the NSW State Department of Health is a significant milestone for the Company. It will allow CannPal to facilitate the supply of cannabis to our research partners In order to commence the clinical phase of our development plan for CPAT-01. The authorisation is a key step in the Company’s plans to import medical cannabis for the purpose of scientific research in companion animals.